This ‘Primary Biliary Cholangitis (PBC) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of primary biliary cholangitis in the United States, EU4 (Germany, Spain, Italy, France) and the UK, Japan, and China.
Patients with PBC can be asymptomatic or may present with jaundice, pruritus, and fatigue. Other symptoms may include abdominal pain, skin darkening, and xanthomas or xanthelasmas. Individuals may also complain of dry mouth, eyes, bone, muscle, and joint pain. As the disease progresses, symptoms of cirrhosis can develop, including jaundice, edema, ascites, and varices.
Since many people with PBC have no symptoms, the disease is often discovered incidentally due to abnormal results on routine liver blood tests. Once PBC is suspected, a blood test is done to check for anti-mitochondrial antibodies (AMA). This test is positive in nearly all people with PBC. A liver biopsy, where a small sample of liver tissue is removed with a small needle, can help confirm the diagnosis. Imaging studies may rule out other diseases or evaluate patients further once diagnosed with PBC.
There are only two medications approved by the Food and Drug Administration (FDA) to treat PBC; ursodeoxycholic acid (UDCA) and obeticholic acid (OCALIVA). UDCA is a hydrophilic bile salt that stabilizes hepatocyte membranes against toxic bile salts and inhibits apoptosis and fibrosis. While, obeticholic acid is a farnesoid X receptor agonist that helps reduce ALP, GGT, and transaminase levels due to its antifibrotic and choleretic properties. It can be given in combination with UDCA in adults with inadequate response to UDCA or as a single therapy in adults unable to tolerate UDCA.
Epidemiology
The primary biliary cholangitis epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
In 2021, the total diagnosed prevalent cases of PBC were more than 1,000,000 in the 7MM + China.
As per the estimates, China had the highest diagnosed prevalent patient population of PBC in 2021. Among EU4 and the UK, Germany had the highest number of diagnosed cases of PBC, with around 32,000 cases, followed by the UK in 2021. On the other hand, Spain had the lowest number of diagnosed cases of PBC, with close to 10,000 cases in 2021.
Primary Biliary Cholangitis: Disease Understanding
Primary Biliary Cholangitis Overview
According to the American Liver Foundation, primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease resulting from the progressive destruction of the bile ducts in the liver, called the intrahepatic bile ducts. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension.Patients with PBC can be asymptomatic or may present with jaundice, pruritus, and fatigue. Other symptoms may include abdominal pain, skin darkening, and xanthomas or xanthelasmas. Individuals may also complain of dry mouth, eyes, bone, muscle, and joint pain. As the disease progresses, symptoms of cirrhosis can develop, including jaundice, edema, ascites, and varices.
Since many people with PBC have no symptoms, the disease is often discovered incidentally due to abnormal results on routine liver blood tests. Once PBC is suspected, a blood test is done to check for anti-mitochondrial antibodies (AMA). This test is positive in nearly all people with PBC. A liver biopsy, where a small sample of liver tissue is removed with a small needle, can help confirm the diagnosis. Imaging studies may rule out other diseases or evaluate patients further once diagnosed with PBC.
There are only two medications approved by the Food and Drug Administration (FDA) to treat PBC; ursodeoxycholic acid (UDCA) and obeticholic acid (OCALIVA). UDCA is a hydrophilic bile salt that stabilizes hepatocyte membranes against toxic bile salts and inhibits apoptosis and fibrosis. While, obeticholic acid is a farnesoid X receptor agonist that helps reduce ALP, GGT, and transaminase levels due to its antifibrotic and choleretic properties. It can be given in combination with UDCA in adults with inadequate response to UDCA or as a single therapy in adults unable to tolerate UDCA.
Epidemiology
The primary biliary cholangitis epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted Primary Biliary Cholangitis epidemiology segmented as the Diagnosed Prevalent Cases of Primary Biliary Cholangitis, Gender-specific Cases of Primary Biliary Cholangitis, and Age-specific Cases of Primary Biliary Cholangitis. The report includes the total cases of PBC in the 7MM + China covering the United States, EU4 and the United Kingdom, Japan, and China, from 2019 to 2032.Country-wise Primary Biliary Cholangitis Epidemiology
The epidemiology segment also provides the primary biliary cholangitis epidemiology data and findings across the United States, EU4 and the United Kingdom, Japan, and China.In 2021, the total diagnosed prevalent cases of PBC were more than 1,000,000 in the 7MM + China.
As per the estimates, China had the highest diagnosed prevalent patient population of PBC in 2021. Among EU4 and the UK, Germany had the highest number of diagnosed cases of PBC, with around 32,000 cases, followed by the UK in 2021. On the other hand, Spain had the lowest number of diagnosed cases of PBC, with close to 10,000 cases in 2021.
Scope of the Report
- The primary biliary cholangitis report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
- Primary biliary cholangitis epidemiology report and model provide an overview of the risk factors and global trends of primary biliary cholangitis in the seven major markets and China (The 7MM + China: The US, France, Germany, Italy, Spain, the UK, Japan, and China).
- The report provides insight into the historical and forecasted patient pool of primary biliary cholangitis in the seven major markets and China covering the United States, EU4 and the UK, Japan, and China.
- The report helps recognize the growth opportunities in the 7MM + China concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of primary biliary cholangitis.
- The report provides the segmentation of the primary biliary cholangitis epidemiology by the diagnosed prevalent cases of primary biliary cholangitis, mutation-specific cases of primary biliary cholangitis, and comorbidity associated with primary biliary cholangitis in the 7MM + China.
Report Highlights
- 11-year Forecast of Primary Biliary Cholangitis Epidemiology
- The 7MM + China Coverage
- Diagnosed Prevalent Cases of Primary Biliary Cholangitis
- Gender-specific Cases of Primary Biliary Cholangitis
- Age-specific Cases of Primary Biliary Cholangitis
KOL Views
The publisher interviews KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern, and this will support the clients in potential novel treatments by identifying the overall scenario of the indications.Key Questions Answered
- What major factors will drive the change in the patient population in an indication of primary biliary cholangitis during the forecast period (2019-2032)?
- What key findings about Primary Biliary Cholangitis epidemiology across the 7MM + China, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of patients with primary biliary cholangitis across the 7MM + China forecast period (2019-2032)?
- Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR is the patient population expected to grow in the 7MM + China forecast period (2019-2032)?
- What are the disease risk, burdens, and unmet needs of primary biliary cholangitis?
- What are the currently available treatments for primary biliary cholangitis?
Reasons to Buy
Primary biliary cholangitis epidemiology report will allow the user to:- Develop business strategies by understanding the trends shaping and driving the global primary biliary cholangitis market.
- Quantify patient populations in the global primary biliary cholangitis market to improve product design, pricing, and launch plans.
- Understand the magnitude of the primary biliary cholangitis population by its diagnosed prevalent cases, mutation-specific cases, and comorbidity associated with primary biliary cholangitis.
- The primary biliary cholangitis epidemiology report and model were written and developed by Masters and PhD epidemiologists.
- The primary biliary cholangitis epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU4 and the United Kingdom
- Japan
- China
Table of Contents
1. Key Insights2. Report Introduction
3. Primary Biliary Cholangitis (PBC) Market Overview at a Glance
3.1. Patient Share (%) Distribution of PBC in 2019
3.2. Patient Share (%) Distribution of PBC in 2032
4. Executive Summary of Primary Biliary Cholangitis (PBC)
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
7.1. Introduction
7.2. Symptoms
7.3. Etiology
7.4. Pathogenesis
7.4.1. Genetics, epigenetics, and environmental factors in PBC pathogenesis
7.5. Complications of PBC
7.5.1. Hepatic complications of PBC
7.5.2. Extrahepatic complications of PBC
7.6. Diagnosis
7.6.1. Diagnostic Guidelines
7.7. Treatment
7.7.1. Treatment options
7.7.2. Approved treatments for an incomplete response to UDCA
7.7.3. Symptomatic treatment of PBC
7.7.4. Management of hepatic complications in PBC
7.8. Treatment Guidelines
7.8.1. American Association for the Study of Liver Diseases (AASLD) 2018 Practice Guidelines
7.8.2. European Association for Study of Liver (EASL) Clinical Practice Guidelines
7.8.3. The British Society of Gastroenterology/UK PBC Treatment and Management Guidelines
7.8.4. Chinese Guidelines on the Management of Liver Cirrhosis
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Total Diagnosed Prevalent Cases of PBC in the 7MM + China
8.4. The US
8.4.1. Diagnosed prevalent cases of PBC in the US
8.4.2. Gender-specific cases of PBC in the US
8.4.3. Age-specific cases of PBC in the US
8.5. EU4 and the UK
8.5.1. Diagnosed Prevalent Cases of PBC in EU4 and the UK
8.5.2. Gender-specific cases of PBC in EU4 and the UK
8.5.3. Age-specific cases of PBC in EU4 and the UK
8.6. Japan
8.6.1. Diagnosed prevalent cases of PBC in Japan
8.6.2. Gender-specific cases of PBC in Japan
8.6.3. Age-specific cases of PBC in Japan
8.7. China
8.7.1. Diagnosed prevalent cases of PBC in China
8.7.2. Gender-specific cases of PBC in China
8.7.3. Age-specific cases of PBC in China
9. Patient Journey
10. KOL Views
11. Unmet Needs
12. Appendix
12.1. Bibliography
12.2. Acronyms and Abbreviations
12.3. Report Methodology
13. Publisher Capabilities
14. Disclaimer
15. About the Publisher
List of Tables
Table 1: Summary of PBC, Market, and Epidemiology (2019-2032)
Table 2: Key Events
Table 3: Clinical Features of Primary Biliary Cirrhosis
Table 4: Currently Known Epigenetic Modifications Described in PBC
Table 5: Grading evidence and recommendations (adapted from the GRADE system)
Table 6: EASL Clinical Practice Guidelines: The diagnosis and Management of Patients With PBC
Table 7: Overview of the Utility of Investigation in PBC
Table 8: The British Society of Gastroenterology/UK recommendations
Table 9: Scoring Systems Used to Assess UDCA Treatment Response
Table 10: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Table 11: EASL Clinical Practice Guidelines
Table 12: The British Society of Gastroenterology/UK recommendations
Table 13: Chinese Recommendations for Liver Cirrhosis
Table 14: Total Diagnosed Prevalent Cases of PBC in the 7MM + China (2019-2032)
Table 15: Total Diagnosed Prevalent Cases of PBC in the US (2019-2032)
Table 16: Gender-specific Cases of PBC in the US (2019-2032)
Table 17: Age-specific Cases of PBC in the US (2019-2032)
Table 18: Total Diagnosed Prevalent Cases of PBC in EU4 and the UK (2019-2032)
Table 19: Gender-specific Cases of PBC in EU4 and the UK (2019-2032)
Table 20: Age-specific Cases of PBC in EU4 and the UK (2019-2032)
Table 21: Total Diagnosed Prevalent Cases of PBC in Japan (2019-2032)
Table 22: Gender-specific Cases of PBC in Japan (2019-2032)
Table 23: Age-specific Cases of PBC in Japan (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of PBC in China (2019-2032)
Table 25: Gender-specific Cases of PBC in China (2019-2032)
Table 26: Age-specific Cases of PBC in China (2019-2032)
List of Figures
Figure 1: Symptoms of Primary Biliary Cholangitis
Figure 2: The Pathogenesis of PBC
Figure 3: Histology of PBC
Figure 4: EASL Clinical Practice Guideline in PBC Consensus Management Flow Chart
Figure 5: EASL The BSG/UK-PBC Consensus Care Pathway for Patients With PBC
Figure 6: Total Diagnosed Prevalent Cases of PBC in the 7MM + China (2019-2032)
Figure 7: Total Diagnosed Prevalent Cases of PBC in the US (2019-2032)
Figure 8: Gender-specific Cases of PBC in the US (2019-2032)
Figure 9: Age-specific Cases of PBC in the US (2019-2032)
Figure 10: Total Diagnosed Prevalent Cases of PBC in EU4 and the UK (2019-2032)
Figure 11: Gender-specific Cases of PBC in EU4 and the UK (2019-2032)
Figure 12: Age-specific Cases of PBC in EU4 and the UK (2019-2032)
Figure 13: Total Diagnosed Prevalent Cases of PBC in Japan (2019-2032)
Figure 14: Gender-specific Cases of PBC in Japan (2019-2032)
Figure 15: Age-specific Cases of PBC in Japan (2019-2032)
Figure 16: Total Diagnosed Prevalent Cases of PBC in China (2019-2032)
Figure 17: Gender-specific Cases of PBC in China (2019-2032)
Figure 18: Age-specific Cases of PBC in China (2019-2032)
